Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates and working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 MEA
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Antiviral drugs market industry 3600 synopsis
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Indication trends
2.1.4 Type trends
2.1.5 Age group trends
2.1.6 Regional trends
Chapter 3 Antiviral Drugs Market Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising prevalence of viral infections including COVID-19
3.3.1.2 Increasing number of product launches for HIV treatment
3.3.1.3 High investment in R&D activities and presence of pipeline products
3.3.1.4 Increasing geriatric population
3.3.2 Industry pitfalls & challenges
3.3.2.1 Presence of generics
3.3.2.2 Rising awareness about preventive drugs treatment
3.3.2.3 Drug resistance
3.4 Growth potential analysis
3.4.1 By drug class
3.4.2 By indication
3.4.3 By type
3.4.4 By age group
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 Competitive landscape, 2021
3.9 PESTEL analysis
Chapter 4 Antiviral Drugs Market, By Drug Class
4.1 Key segment trends
4.2 DNA polymerase inhibitors
4.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Reverse transcript inhibitors
4.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.4 Protease inhibitors
4.4.1 Market size, by region, 2017 - 2028 (USD Million)
4.5 Neuraminidase inhibitors
4.5.1 Market size, by region, 2017 - 2028 (USD Million)
4.6 Others
4.6.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 5 Antiviral Drugs Market, By Indication
5.1 Key segment trends
5.2 Influenza
5.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.3 HIV AIDS
5.3.1 Market size, by region, 2017 - 2028 (USD Million)
5.4 Hepatitis
5.4.1 Market size, by region, 2017 - 2028 (USD Million)
5.5 Herpes simplex virus (HSV)
5.5.1 Market size, by region, 2017 - 2028 (USD Million)
5.6 Coronavirus infection
5.6.1 Market size, by region, 2017 - 2028 (USD Million)
5.7 Others
5.7.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 6 Antiviral Drugs Market, By Type
6.1 Key segment trends
6.2 Branded
6.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.3 Generic
6.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 7 Antiviral Drugs Market, By Age Group
7.1 Key segment trends
7.2 Adult
7.2.1 Market size, by region, 2017 - 2028 (USD Million)
7.3 Pediatric
7.3.1 Market size, by region, 2017 - 2028 (USD Million)
7.4 Geriatric
7.4.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 8 Antiviral Drugs Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country, 2017 - 2028 (USD Million)
8.2.2 Market size, by drug class, 2017 - 2028 (USD Million)
8.2.3 Market size, by indication, 2017 - 2028 (USD Million)
8.2.4 Market size, by type, 2017 - 2028 (USD Million)
8.2.5 Market size, by age group, 2017 - 2028 (USD Million)
8.2.6 U.S.
8.2.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.2.6.2 Market size, by indication, 2017 - 2028 (USD Million)
8.2.6.3 Market size, by type, 2017 - 2028 (USD Million)
8.2.6.4 Market size, by age group, 2017 - 2028 (USD Million)
8.2.7 Canada
8.2.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.2.7.2 Market size, by indication, 2017 - 2028 (USD Million)
8.2.7.3 Market size, by type, 2017 - 2028 (USD Million)
8.2.7.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3 Europe
8.3.1 Market size, by country, 2017 - 2028 (USD Million)
8.3.2 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.3 Market size, by indication, 2017 - 2028 (USD Million)
8.3.4 Market size, by type, 2017 - 2028 (USD Million)
8.3.5 Market size, by age group, 2017 - 2028 (USD Million)
8.3.6 Germany
8.3.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.6.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.6.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.6.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.7 UK
8.3.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.7.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.7.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.7.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.8 France
8.3.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.8.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.8.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.8.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.9 Spain
8.3.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.9.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.9.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.9.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.10 Italy
8.3.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.10.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.10.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.10.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.11 Russia
8.3.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.11.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.11.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.11.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.12 Poland
8.3.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.12.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.12.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.12.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.13 Switzerland
8.3.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.13.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.13.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.13.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.14 The Netherlands
8.3.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.14.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.14.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.14.4 Market size, by age group, 2017 - 2028 (USD Million)
8.3.15 Sweden
8.3.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.3.15.2 Market size, by indication, 2017 - 2028 (USD Million)
8.3.15.3 Market size, by type, 2017 - 2028 (USD Million)
8.3.15.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4 Asia Pacific
8.4.1 Market size, by country, 2017 - 2028 (USD Million)
8.4.2 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.3 Market size, by indication, 2017 - 2028 (USD Million)
8.4.4 Market size, by type, 2017 - 2028 (USD Million)
8.4.5 Market size, by age group, 2017 - 2028 (USD Million)
8.4.6 Japan
8.4.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.6.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.6.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.6.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.7 China
8.4.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.7.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.7.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.7.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.8 India
8.4.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.8.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.8.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.8.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.9 Australia
8.4.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.9.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.9.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.9.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.10 South Korea
8.4.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.10.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.10.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.10.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.11 Singapore
8.4.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.11.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.11.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.11.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.12 Indonesia
8.4.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.12.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.12.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.12.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.13 Thailand
8.4.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.13.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.13.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.13.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.14 Malaysia
8.4.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.14.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.14.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.14.4 Market size, by age group, 2017 - 2028 (USD Million)
8.4.15 Philippines
8.4.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.4.15.2 Market size, by indication, 2017 - 2028 (USD Million)
8.4.15.3 Market size, by type, 2017 - 2028 (USD Million)
8.4.15.4 Market size, by age group, 2017 - 2028 (USD Million)
8.5 Latin America
8.5.1 Market size, by country, 2017 - 2028 (USD Million)
8.5.2 Market size, by drug class, 2017 - 2028 (USD Million)
8.5.3 Market size, by indication, 2017 - 2028 (USD Million)
8.5.4 Market size, by type, 2017 - 2028 (USD Million)
8.5.5 Market size, by age group, 2017 - 2028 (USD Million)
8.5.6 Brazil
8.5.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.5.6.2 Market size, by indication, 2017 - 2028 (USD Million)
8.5.6.3 Market size, by type, 2017 - 2028 (USD Million)
8.5.6.4 Market size, by age group, 2017 - 2028 (USD Million)
8.5.7 Mexico
8.5.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.5.7.2 Market size, by indication, 2017 - 2028 (USD Million)
8.5.7.3 Market size, by type, 2017 - 2028 (USD Million)
8.5.7.4 Market size, by age group, 2017 - 2028 (USD Million)
8.5.8 Argentina
8.5.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.5.8.2 Market size, by indication, 2017 - 2028 (USD Million)
8.5.8.3 Market size, by type, 2017 - 2028 (USD Million)
8.5.8.4 Market size, by age group, 2017 - 2028 (USD Million)
8.6 Middle East & Africa
8.6.1 Market size, by country, 2017 - 2028 (USD Million)
8.6.2 Market size, by drug class, 2017 - 2028 (USD Million)
8.6.3 Market size, by indication, 2017 - 2028 (USD Million)
8.6.4 Market size, by type, 2017 - 2028 (USD Million)
8.6.5 Market size, by age group, 2017 - 2028 (USD Million)
8.6.6 Saudi Arabia
8.6.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.6.6.2 Market size, by indication, 2017 - 2028 (USD Million)
8.6.6.3 Market size, by type, 2017 - 2028 (USD Million)
8.6.6.4 Market size, by age group, 2017 - 2028 (USD Million)
8.6.7 South Africa
8.6.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.6.7.2 Market size, by indication, 2017 - 2028 (USD Million)
8.6.7.3 Market size, by type, 2017 - 2028 (USD Million)
8.6.7.4 Market size, by age group, 2017 - 2028 (USD Million)
8.6.8 UAE
8.6.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
8.6.8.2 Market size, by indication, 2017 - 2028 (USD Million)
8.6.8.3 Market size, by type, 2017 - 2028 (USD Million)
8.6.8.4 Market size, by age group, 2017 - 2028 (USD Million)
Chapter 9 Company Profiles
9.1 Competitive dashboard, 2021
9.2 Gilead Sciences, Inc
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Johnson & Johnson
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 GlaxoSmithKline
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 AbbVie, Inc
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Merck & Co.,
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Bristol Myers Squibb
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Aurobindo Pharma Limited
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Sun Pharmaceutical Industries Ltd
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Cipla, Inc.
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Mylan N.V.
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
